Concomitantly, compared with the report of the Collaborative Research Group on Thrombolysis which used urokinase in all subjects without using a P2Y12 inhibitor, successful clinical reperfusion strongly increased in the present cohort (from 66.5 to 78.3%) [13], associating with 1-year mortality (6.8%) comparable with those treated with PPCI in the large Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admissions (RIKS-HIA) (7.6%) [10] and the French registry of Acute ST-elevation and non–ST-elevation Myocardial Infarction (FAST-MI) (8.2%) [11]. Here, P2RY12 is linked to myocardial infarction.